๐ฎ๐ณ ์ธ๋ ยท "INFECTIONS" ยท ์ด 4๊ฑด
ํํฐ ๋ณด๊ธฐํ์ฌ ์ง์
50.0
0 = ๋ถ์ ์ฐ์ธ
50 = ์ค๋ฆฝ
100 = ๊ธ์ ์ฐ์ธ
์ต๊ทผ 7์ผ ๊ธฐ์ค 5,725๊ฑด์ ๋ถ์ํ ๊ฒฐ๊ณผ, ๋ด์ค ์ฌ๋ฆฌ์ง์๋ 50.0(๊ท ํ)์ ๋๋ค. ๊ธ์ 0๊ฑด(0.0%)ยท์ค๋ฆฝ 5,725๊ฑด(100.0%)ยท๋ถ์ 0๊ฑด(0.0%)์ด๋ฉฐ, ์ค๋ฆฝ ๋น์ค์ด ๋๋ ทํ๊ฒ ๋์ต๋๋ค. ์ฑํฅ ์ง์๋ ์ข ํฉ 0.0(์ค๋ ๊ท ํ)์ ๋๋ค.
It reflects the large number of young patients with demanding lifestyles who undergo these surgeries and subsequently experience complications.
Shares of Indian IT companies, including heavyweights Infosys, Tech Mahindra, TCS and Persistent Systems jumped up to 5% on Monday as multiple tailwinds boosted investor sentiment, pushing the Nifty IT index up around 3% to emerge as the top sectoral gainer.The index rose to 29,905 in the morning trading hours of Monday, extending sharp gains for the second consecutive session. The index has now jumped nearly 4% over two days.The sharp surge in IT stocks comes after a significant decline earlier this year, following the launch of plug-ins for AI startup Anthropic's Claude Cowork agent, which could automate tasks across legal, sales, marketing, and data analysis. "We call it the โSaaSpocalypse,โ an apocalypse for software-as-a-service stocks," Bloomberg quoted Jeffrey Favuzza from the equity trading desk at Jefferies as saying.While doomsday prophets continue to debate the future of IT companies following fresh AI advancements, investors were quick to analyse the cheap valuations, leading to some pockets of buying. Nuvama, in its note, had highlighted that the IT sector is setting up for a powerful comeback, not a collapse after the brutal AI-driven selloff.โWe see no existential threat from Gen-AI,โ the brokerage writes, arguing that enterprises will still need a โsystem integratorโ to customise plug-and-play AI and software tools for their highly complex, brownfield technology stacks and to take ownership when โthe system fails at 2 am.โAlso read: Reports of my death are greatly exaggerated! Why Nuvama is screaming buy on all top 10 IT stocksThe latest round of buying also comes ahead of the Federal Reserveโs policy meeting next month, which would be the first under Chair Kevin Warsh. US President Donald Trump had selected Warsh partly on expectations that he would support lower borrowing costs to stimulate economic growth. However, rising inflation raised questions over the possibility of lowering rates.Technical view on Nifty ITThe Nifty IT index has witnessed a strong rebound after taking support near its crucial support zone, indicating the possibility of a short-term recovery in the sector, Kunal Kamble, Senior Technical Research Analyst at Bonanza had said. โOn the hourly time frame, the index is currently forming an inverse Head and Shoulders pattern. A decisive breakout is seen above the neckline of this pattern and has triggered further upside momentum in the index. Such a move is likely to positively impact heavyweight IT stocks that share a high correlation with the index, including Infosys, Tata Consultancy Services, and HCL Technologies,โ he added.Technically, the analyst had suggested that if the index manages to sustain above the 29,650 mark, it may open the door for a further recovery towards the 31,280 zone in the near term. However, he added that the current price action appears to be a retracement within the broader trend rather than a complete trend reversal. Therefore, traders should approach the sector with a cautious outlook.โAggressive or high-risk traders may consider short-term trading opportunities in select IT counters, provided the index maintains strength above key support levels. On the downside, a breach below 28,800 could once again invite selling pressure across the Nifty IT index and associated IT stocks, potentially weakening the ongoing recovery structure,โ he said.IT stocksPersistent Systems shares were the top gainers on the Nifty IT index, jumping nearly 5%. Infosys shares followed, surging nearly 4%. Mphasis, Tech Mahindra, LTI Mindtree and Coforge shares gained over 3% each.Also read: Wockhardt shares rocket 19% after FDA approval for antibiotic targeting drug-resistant infectionsTata Consultancy Services (TCS) and OFSS shares jumped around 2% each, while HCL Technologies and Wipro shares gained around 1% each.(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Shares of Wockhardt soared as much as 19% to their day's high of Rs 2,420 on the BSE on Monday after the company announced that the U.S. Food and Drug Administration (FDA) has approved ZAYNICH (cefepime and zidebactam), a novel intravenous antibiotic for the treatment of adults with complicated urinary tract infections (UTI), including pyelonephritis, caused by susceptible Gram-negative pathogens.According to the company, ZAYNICH combines the fourth-generation cephalosporin cefepime with zidebactam and is designed to target multiple penicillin-binding proteins simultaneously. The antibiotic had earlier received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA.The approval comes at a time when antimicrobial resistance remains a major healthcare challenge. Wockhardt cited data indicating that more than 2.8 million antimicrobial-resistant infections occur annually in the United States, resulting in over 35,000 deaths each year. The company also noted that complicated urinary tract infections account for more than 6,00,000 hospitalisations annually in the U.S., with a growing proportion linked to antimicrobial-resistant and multidrug-resistant bacteria.The FDA's decision was based in part on results from the Phase 3 ENHANCE-1 study, a randomised, double-blind, multicentre trial that evaluated the efficacy, safety and tolerability of ZAYNICH against meropenem in hospitalised adults with complicated urinary tract infections or acute pyelonephritis.In the study, ZAYNICH achieved a composite clinical cure and microbiological response rate of 89% at the test-of-cure visit, compared with 68.4% for meropenem. The treatment difference was 20.6% with a 95% confidence interval of 12.3 to 29.5. The company said the drug was generally well tolerated during the trial.The ENHANCE-1 study enrolled 530 patients across 64 sites spanning the United States, Europe, Latin America, China and India.Wockhardt stated that ZAYNICH targets penicillin-binding proteins PBP 1a/b, 2 and 3 simultaneously, a mechanism that it says provides bactericidal activity against multidrug-resistant Gram-negative bacteria for which treatment options remain limited.The company also disclosed that ZAYNICH received approval from the Drugs Controller General of India (DCGI) on May 27, 2026. In addition, Wockhardt has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency for the antibiotic.Sensex, Nifty today: Catch all the LIVE stock market action here (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Wockhardt shares rallied sharply on Friday, surging 7.87% to hit Rs 1,910.50 after the pharmaceutical company received a major regulatory boost for its breakthrough antibiotic, Zaynich. Notably, the stock has climbed nearly 12% in just the last two trading sessions, reflecting strong investor optimism following the development.In an exchange filing, Wockhardt announced that the Central Drugs Standard Control Organisation (CDSCO) has approved the import and marketing of its indigenously discovered and developed first-in-class antibiotic, Zaynich (Zidebactam/Cefepime), in India.The approval covers the treatment of adult patients suffering from complicated urinary tract infections (cUTI), including pyelonephritis, as well as cases involving concurrent Gram-negative bacteremia.The nod is backed by strong results from the pivotal ENHANCE-1 Phase 3 clinical trial, a multinational, randomised, double-blind study comparing Zaynich with Meropenem โ one of the widely used antibiotics for severe infections.The results significantly favoured Zaynich. The study showed that 89% of patients treated with Zaynich achieved clinical cure and microbiological eradication, compared with 68.4% in the Meropenem arm, delivering a treatment advantage of 20.6%.Even more striking were the outcomes in high-risk bacteremia patients, where Zaynich posted an 89% response rate versus just 44% for Meropenem, highlighting its potential as a game-changing therapy in severe drug-resistant infections.The company stated that Zaynich could emerge as a critical weapon against carbapenem-resistant infections โ an area where existing treatment options like colistin and polymyxins often face limitations due to toxicity and weaker efficacy. Importantly, the drug is designed to combat metallo-ฮฒ-lactamase (MBL)-mediated resistance, one of the toughest and most widespread antibiotic resistance mechanisms in India.Wockhardt Shares: Price trend and technical outlookWockhardt shares have surged nearly 27% over the past month, while the stock has skyrocketed an astounding 946% in the last three years, turning investor wealth nearly 10-fold during the period. The company currently commands a market capitalisation of around Rs 28,777 crore.On the technical front, Trendlyne data indicates that Wockhardtโs 14-day Relative Strength Index (RSI) stands at 72.3. An RSI above 70 is generally considered overbought, suggesting the stock could witness some profit-booking or a short-term pullback after the recent sharp rally.However, the overall trend remains firmly bullish, with the stock trading above all 8 out of 8 key simple moving averages (SMAs), indicating sustained strength in momentum.(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)